Dual regulation of SLC25A39 by AFG3L2 and iron controls mitochondrial glutathione homeostasis Xiaojian Shi 1 , Marisa DeCiucis 1 , Kariona A . Grabinska 1 , Jean Kanyo 2 , Adam Liu 3 , Tukiet Lam 2 , Hongying Shen 1 * 1 Cellular and Molecular Physiology Department , Yale School of Medicine , New Haven , CT , USA ; Systems Biology Institute , Yale West Campus , West Haven , CT , USA 2 Keck MS & Proteomics Resource ; Yale / NIDA Neuroproteomics Center , Yale University , New Haven , CT , USA 3 Amity High School , Woodbridge , CT , USA * Correspondence : hongying . shen @ yale . edu ( H . S . ) Summary Organelle transporters define metabolic compartmentalization and how this metabolite transport process can be modulated is poorly explored . Here , we discovered that SLC25A39 , a mitochondrial transporter critical for mitochondrial glutathione uptake , is a short - lived protein under dual regulation at the protein level . Co - immunoprecipitation mass spectrometry and CRISPR KO in cells identified that mitochondrial m - AAA protease AFG3L2 is responsible for degrading SLC25A39 through the matrix loop 1 . SLC25A39 senses mitochondrial iron - sulfur cluster using four matrix cysteine residues and inhibits its degradation . SLC25A39 protein regulation is robust in developing and mature neurons . This dual transporter regulation , by protein quality control and metabolic sensing , allows modulating mitochondrial glutathione level in response to iron homeostasis , opening new avenues to explore regulation of metabolic compartmentalization . Neuronal SLC25A39 regulation connects mitochondrial protein quality control , glutathione and iron homeostasis , which were previously unrelated biochemical features in neurodegeneration . Introduction Mitochondrial metabolite transporters 1 - 3 define metabolic compartmentalization between mitochondria and rest of the cell 4 , and transport dysregulation is associated with many pathological conditions such as neurodegenerations , metabolic syndromes and cancers . Despite the recent discoveries of protein identities that facilitate metabolite transport , the mechanism by which transporter proteins can be regulated remain unexplored . Given the critical role of mitochondrial redox metabolism and oxidative stress 5 - 8 in physiology , we focus on the regulation of mitochondrial transport for glutathione , the most abundant endogenous antioxidant . Glutathione 9 critically supports redox signaling and biosynthesis of iron - sulfur ( Fe - S ) cluster cofactors inside the mitochondrial matrix 10 - 12 . Because glutathione is exclusively synthesized in the cytosol , how glutathione enters the mitochondrial matrix remained a decades - old mystery until the recent identification that a previously uncharacterized mitochondrial metabolite transporter , SLC25A39 ( A39 ) , is critical for mitochondrial glutathione transport 13 - 15 . A39 belongs to the SoLute Carrier 25 ( SLC25 ) family , the largest transporter family that is responsible for translocating diverse metabolite ligands across the mitochondrial inner membrane 1 - 3 . Despite the relatively small mitochondrial volume , mitochondrial glutathione accounts for 10 - 15 % of the total cellular glutathione pool 10 . We therefore hypothesize that a direct regulation of A39 could have a major impact on glutathione compartmentalization and cellular metabolism . Results SLC25A39 protein regulation depends on GSH and the matrix cysteine residues . To explore the regulatory mechanism of A39 , we performed amino acid sequence analysis 14 , 16 and Alphafold structure prediction 17 of A39 . In addition to the typical structural fold , the threefold pseudo - symmetrical , six transmembrane a - helices surrounding the central transport cavity , the analysis revealed that A39 contains an extra mitochondrial matrix loop between transmembrane domain 1 and 2 with a low structural prediction confidence score ( Fig . 1A ) . This loop 1 of amino acids 41 - 105 contains four matrix side surface - exposed , thiol Cysteine ( Cys ) residues 18 , 19 ( Fig . 1A ) , which exceeds Cys frequency in proteins at around 1 . 7 % 20 . C - terminal FLAG - tagged A39 construct with all four cysteines mutated to alanine , A39 4CA - FLAG , can fully restore mitochondrial GSH depletion in the A39 CRISPR KO cells similar to the wild type A39 - FLAG ( Fig . 1C ) , suggesting that the A39 4CA mutant is an active transporter , while another cysteine mutant of the substrate binding site A39 C334S - FLAG can only rescue partially ( Fig . 1C ) . However , A39 4CA - FLAG completely abolished A39 protein upregulation upon pharmacological inhibition of glutathione biosynthesis using buthionine sulphoximine ( BSO ) ( Fig . 1B ) , a regulation specific to A39 protein at the post - transcriptional level ( Fig . S1A - C ) that was previously reported with an unknown mechanism 13 . SLC25A39 is a short - lived protein and degradation is regulated by cysteine residues . Because ectopically expressed recombinant A39 - FLAG protein can only be expressed as a level similar to that of the endogenous A39 ( Fig . 1B ) , we suspected that A39 protein might be tightly maintained at a low level under basal condition that is then alleviated upon GSH depletion by BSO . Indeed , we first identified that human A39 protein level is extremely low in comparison to the A39 mRNA level , which stands out as a proteome - wide outlier of protein - mRNA correlation in the HEK293T cells ( CZI Open Cell 21 , Fig . 1D ) ¾ the majority of the mitochondrial SLC25 transporters exhibit correlated protein and mRNA levels ( Fig . 1D ) . Because all inner membrane SLC25 transporters are imported through a common TIM22 import mechanism , we suspected that A39 protein stability is regulated . We then performed cycloheximide ( CHX ) chase experiments and discovered that pre - synthesized A39 protein indeed exhibited a very short half - life < 2 hrs under basal condition ( Fig . 1E ) . A39 4CA protein exhibited a similar short half - life ( Fig . 1F ) . This half - life is drastically shorter than the majority of mitochondrial proteins 22 , 23 of approximately median half - life at 87 h 24 . BSO significantly extended A39’s half - life ( Fig . 1E ) , but failed to extend the short half - life of A39 4CA ( Fig . 1F ) . This suggests that under basal condition , both pre - synthesized wild - type A39 and A39 4CA mutant were quickly degraded , and BSO treatment inhibited A39 degradation through a mechanism that depends on the matrix cysteines . These two regulatory mechanisms of A39 , both fast degradation and BSO - mediated stabilization , are yet to be explored . Mitochondrial m - AAA protease AFG3L2 is responsible for A39 degradation . To characterize the quality control pathway that degrades A39 , we combined co - immunoprecipitation mass spectrometry ( MS ) and CRISPR KO in cells to identify its regulatory machinery . We first selected K562 clonal cells ectopically expressing relatively high level of A39 - FLAG and a mitochondrial tag ( HA - MITO , 3xHA - eGFP - OMP25 25 , 26 ) from the clonal A39 CRISPR KO cells ( Fig . 2A and S2A ) . We treated the cells with BSO for 2 days to increase the A39 - FLAG protein level ( Fig . S2A ) , rapidly immuno - isolated the mitochondria via HA - MITO using anti - HA magnetic beads , and then immunoprecipitated A39 binding partners using anti - FLAG resin in a mild 1 % digitonin - containing lysates ( Fig . 2A ) . Wild type K562 cell expressing HA - MITO tag was used as the control . Silver staining of the immunoprecipitants revealed an enrichment of A39 - FLAG protein that migrated around 40 kD , confirmed by MS ( Fig . 2A ) . One major band around 60kD that is specific to A39 - FLAG IP was identified as HSPD1 / HSP60 by MS ( Fig . 2A ) , an abundant mitochondrial matrix chaperonin that facilitates folding and refolding of matrix proteins 27 . HSPD1 enrichment suggested that the matrix portion of A39 protein may be flexible and misfolded , however , because HSPD1 CRISPR KO did not affect A39 protein level under basal condition ( Fig . 2C ) , we did not follow up here . We then performed MS analysis of the entire gel lane from the A39 - FLAG immunoprecipitants and control to identify specific A39 binding partners ( Supplementary Data 1 ) . We categorized the hits into pathways relevant to mitochondrial quality control and A39 - related metabolite sensing mechanisms that include mitochondrial proteases , matrix chaperones , mitophagy - related , and iron - related proteins ( Fig . 2B ) . We then performed CRISPR to knock out 11 representative protein hits from these pathways to investigate the impact on A39 protein level , both under basal condition and BSO treatment ( Fig . 2C ) . Strikingly , CRISPR KO of only two proteins dramatically stabilized A39 under basal condition , AFG3L2 and ABCB7 ( Fig . 2C , red ) , among which AFG3L2 KO upregulated basal A39 protein level to a much higher level and A39 level in the AFG3L2 KO was no longer sensitive to BSO treatment ( Fig . 2C ) . AFG3L2 is the subunit of the mitochondrial m - AAA proteases in the inner membrane with catalytic sites facing the matrix 28 , and its mutations cause neurological disorders including dominant spinocerebellar ataxia ( SCA28 ) 29 and Spastic ataxia 5 , autosomal recessive ( SPAX5 ) 30 . AFG3L2 CRISPR KO increased the basal level of endogenous A39 , A39 - FLAG and A39 4CA - FLAG ( Fig . 2D ) , suggesting its role in the quality control of A39 ( and A39 4CA ) under basal condition . ABCB7 is a mitochondrial inner membrane protein and a putative transporter for certain iron - sulfur cluster ( Fe - S ) species 31 . Because ABCB7 CRISPR KO only increased wild - type A39 - FLAG but not A39 4CA - FLAG ( Fig . 2E ) , we suspected that ABCB7 might function in the second branch of the regulation , the BSO - mediated A39 stabilization that depends on the matrix cysteines . The quality control regulation of A39 protein is specific to AFG3L2 . Two hexametric m - AAA proteases exist in human , homo - oligomeric AFG3L2 complexes and hetero - oligomeric complexes of the homologous AFG3L2 and SPG7 32 , 33 . Together with i - AAA protease active in the intermembrane space YME1L and other membrane - bound peptidases , they play a central role for inner membrane protein quality control . Notably , our co - immunoprecipitation MS did not recover SPG7 and YME1L , and CRISPR KO of SPG7 and YME1L did not affect A39 protein level ( Fig . 2C ) , suggesting a specificity by AFG3L2 . CHX chase experiment identified that AFG3L2 CRISPR KO completely abolished A39 degradation beyond 8 hrs ( Fig . 2G and H ) - - a complete stabilization upon AFG3L2 loss is different from the moderate BSO - mediated stabilization ( Fig . 1E ) . This suggests that A39 is a specific , short - lived substrate of AFG3L2 , and other mitochondrial proteases cannot compensate and substitute for A39 proteolytic regulation . We validated these findings in HeLa cells , in which AFG3L2 CRISPR KO cells also upregulated A39 level that can be reduced by re - expressing AFG3L2 - 3xFLAG ( Fig . 2F ) . We therefore concluded that AFG3L2 is necessary for degrading A39 under basal condition and this function cannot be substituted by other mitochondrial proteases . A39 degradation is targeted through the matrix loop 1 , which fine - tunes mitochondrial glutathione level . We then tested whether the matrix loop 1 of A39 is responsible for A39 degradation by AFG3L2 . We generated two A39 fusion constructs by swapping the long A39 loop 1 to the corresponding loop of either the homologous transporter SLC25A40 ( A40 ) , A39 A40L1 - FLAG , or to that of the dicarboxylate SLC25 transporter SLC25A11 ( A11 ) , A39 A11L1 - FLAG ( Fig 3A and B ) . As expected , due to the shorter sequences , A39 A11L1 - FLAG and A39 A40L1 - FLAG migrated at lower molecular weights than A39 - FLAG ( Fig . 3C ) . Importantly , A39 A11L1 - FLAG and A39 A40L1 - FLAG were expressed at a much higher level than A39 - FLAG under basal condition ( Fig . 3C ) , and AFG3L2 CRISPSR KO cannot further stabilize these two fusion proteins ( Fig . 3C ) , suggesting they were resistant to degradation . A lack of AFG3L2 - mediated degradation for the loop 1 - swapping A39 fusion constructs strongly suggested that A39’s matrix loop 1 is responsible for AFG3L2 recognition and degradation . We then explored the functional consequence of A39 upregulation on mitochondrial glutathione level using three different experimental conditions . First , we performed mitochondrial metabolite profiling in the AFG3L2 CRISPR KO cells upon rapid mitochondrial immunoisolation using HA - MITO tag and discovered that the KO mitochondria lacking the protease had a higher A39 protein level as expected ( Fig . 3D ) , and increased GSH level ( Fig . 3E ) . Second , we immunoisolated mitochondria from BSO - treated A39 CRISPR KO cells expressing either A39 - FLAG or A39 4CA - FLAG where only A39 - FLAG can be upregulated but not A39 4CA - FLAG ( Fig . 3F ) ; and then performed in vitro mitochondria - based uptake assay using stable isotope labeled GSH [ M + 3 ] ( GSH - [ glycine - 13 C2 , 15 N ] ) for 15 min . The uptake assay revealed significantly higher GSH uptake in the wild type A39 - FLAG expressing cells ( Fig . 3G ) , despite A39 4CA - FLAG is active ( Fig . 1B ) . Third and specifically , we compared mitochondrial glutathione level in the A39 KO cells overexpressing A39 - FLAG or A39 A11L1 - FLAG , in which A39 A11L1 - FLAG is expressed at a much higher level than A39 - FLAG ( Fig . 3H ) . Indeed , while A39 - FLAG can rescue mitochondrial glutathione depletion in the A39 KO cells to the control level , A39 A11L1 - FLAG further increased mitochondrial GSH higher than that of the control level ( Fig . 3I ) . Labeled GSH mitochondrial uptake assay from these cells also confirmed a high mitochondrial glutathione uptake rate ( Fig . 3J ) . Therefore , we concluded that a regulated A39 transporter protein level directly controls mitochondrial matrix glutathione level . SLC25A39 degradation is inhibited by a coordinated sensing of mitochondrial iron - sulfur cluster by the matrix cysteines . What is the mechanism that stabilizes A39 protein during BSO treatment ? We first tested and ruled out the possibility that BSO affects AFG3L2 activity , because BSO treatment does not affect level of NDUFA9 ( Fig . 4A ) , whose degradation depends on AFG3L2 in the mammalian cells 34 . Because previous studies of A39 identified a coupling between A39 and mitochondrial iron homeostasis 13 , 14 , 35 , 36 , we hypothesized a BSO - mediated , A39’s matrix - cysteine - dependent metabolic sensing mechanism . Consistent with this notion , our CRISPR KO assay ( Fig . 2C ) already observed that CRISPR KO of the putative mitochondrial Fe - S cluster transporter ABCB7 stabilized A39 protein in a similar manner that depends on A39’s matrix cysteines ( Fig . 2E ) . Following up on this , we deployed three strategies to perturb iron homeostasis to investigate the impact on A39 protein level ( Fig . 4B ) . First , depleting cellular iron using an iron chelator deferoxamine ( DFO ) , which is sensed by increased cytosolic iron - sensing IRP2 level ( Fig . S3A and S3B ) , diminished BSO - mediated A39 protein upregulation ( Fig . 4C and S3B ) . Second , depleting mitochondrial iron by double CRISPR KO of the two mitochondrial iron transporters , SLC25A28 and SLC25A37 ( Fig . S3C and S3D ) , completely abolished BSO - mediated A39 protein upregulation ( Fig . 4D ) . Third , inhibiting Fe - S cluster biosynthesis chaperone by CRISPR KO of HSCB or GLRX5 ( Fig . S3E and S3F ) significantly dampened BSO - mediated A39 protein upregulation ( Fig . 4E ) . Then , to investigate the contribution of individual matrix cysteines in A39 , we generated four FLAG - tagged single cysteine mutants , A39 C74A , A39 C78A , A38 C88A and A39 C94A . While all four mutants can be expressed similar to the wild - type level under basal condition , all four mutants exhibited reduced stabilization upon BSO treatment ( Fig . S3G ) , suggesting a coordinated regulation through all four cysteines . To assay whether the four matrix cysteines might be directly involved in iron sensing , we applied reactive cysteine labeling reagent , iodoacetyl - PEG2 - biotin ( MW = 542 Da ) , to label cysteine residues of A39 WT - FLAG in the A39 and AFG3L2 KO K562 cell mitochondrial lysates , and assayed iron - dependent labeling efficiency through A39 - FLAG mobility shift ( Fig . 4F ) . Because A39 protein contains three additional cysteine residues besides the four matrix cysteines , we observed a modest mobility shift of the labeled A39 - FLAG from the BSO - treated condition , corresponding to a partial labeling ( Fig . 4G , black asterisk ) . Importantly , cellular iron depletion by either DFO or BSO + DFO treatment allowed A39 - FLAG to be maximally labeled and to migrate at a higher molecular weight ( Fig . 4G , cyan asterisk ) , suggesting more cysteine residues of A39 became exposed upon iron depletion and reactive to labeling . The mobility shift reflects cysteine labeling , because A39 - FLAG from mitochondrial lysates prior to labeling migrated at the similar molecular weight ( Fig . 4G , red asterisk ) and the protein abundance is comparable due to AFG3L2 KO . We therefore concluded that A39’s four matrix cysteines are responsible for coordinated sensing of matrix iron homeostasis , protecting A39 from degradation . A39 regulation in the neuronal cells . Because glutathione , iron , and mitochondrial dysregulation have all been implicated in neurological disorders , we then explored if this A39 protein regulation mechanism also occurs in the neuronal cells . We chose the human induced pluripotent stem cell ( iPSC ) KOLF2 . 1J cell - derived glutamatergic neurons utilizing Tet - On doxycycline ( Dox ) - inducible NGN2 expression ( Fig . 4H ) 37 - 39 . The neuronal differentiation was robust ( > 95 % ) based on neuronal morphology and they were considered mature iNeurons on differentiation Day 21 ( Fig . S3H ) . Western blotting for synaptic marker Synaptophysin confirmed synaptic development ( Fig . 4I ) . We observed a time - dependent reduction of A39 protein level during neuronal differentiation ( Fig . 4I ) , which is accompanied by a decline of the Fe - S cluster machinery HSCB ( Fig . 4I ) , suggesting a coordinated regulation of mitochondrial glutathione and Fe - S cluster during differentiation . The AFG3L2 protein level remained unchanged ( Fig . 4I ) . A39 reduction in neurons is likely due to reduced iron sensing that activates degradation , because BSO treatment in the mature iNeurons dramatically upregulated A39 protein level ( Fig . 4J and 4K ) , which can be dampened by DFO treatment ( Fig . 4K ) . The identification of A39 regulation in the neuronal cells might suggest a regulated neuronal glutathione compartmentalization in the context of brain disorders . Discussion Here , we reported a brand - new dual regulatory mechanism acting on a mitochondrial transporter protein , by both protein quality control and metabolic sensing , which directly controls mitochondrial glutathione level in response to iron homeostasis ( Fig . 4L ) . The proteolytic regulation of A39 is specific to the mitochondrial m - AAA protease AFG3L2 , and cannot be substituted by other mitochondrial proteases that also act around the inner mitochondrial membrane 40 , 41 . A direct sensing of mitochondrial iron homeostasis inhibits A39 degradation , further enabling a specific transporter regulation and coordinated metabolism of two essential and reactive redox metabolites , glutathione and iron , a finding independently reported by Liu et al . 42 . We further went on to reveal this A39 regulation in the developing and mature neurons . This unexpected link between mitochondrial glutathione and m - AAA protease AFG3L2 might lead to new pathophysiological mechanisms under a diverse clinical spectrum of AFG3L2 mutation - associated neurodegenerative disorders that range from ataxia to parkinsonism 29 , 43 . This dual regulatory mechanism of SLC25A39 transporter , by AFG3L2 and iron , further advances our understandings of metabolic regulation through protein quality control and metabolite sensing , opening new avenues to explore the regulation of metabolic compartmentalization in cellular metabolism . 1 . Cunningham , C . N . , and Rutter , J . ( 2020 ) . 20 , 000 picometers under the OMM : diving into the vastness of mitochondrial metabolite transport . EMBO Rep 21 , e50071 . 10 . 15252 / embr . 202050071 . 2 . Kunji , E . R . S . , King , M . S . , Ruprecht , J . J . , and Thangaratnarajah , C . ( 2020 ) . The SLC25 Carrier Family : Important Transport Proteins in Mitochondrial Physiology and Pathology . Physiology ( Bethesda ) 35 , 302 - 327 . 10 . 1152 / physiol . 00009 . 2020 . 3 . Palmieri , F . ( 2013 ) . The mitochondrial transporter family SLC25 : identification , properties and physiopathology . Mol Aspects Med 34 , 465 - 484 . 10 . 1016 / j . mam . 2012 . 05 . 005 . 4 . Bar - Peled , L . , and Kory , N . ( 2022 ) . Principles and functions of metabolic compartmentalization . Nat Metab 4 , 1232 - 1244 . 10 . 1038 / s42255 - 022 - 00645 - 2 . 5 . Balaban , R . S . , Nemoto , S . , and Finkel , T . ( 2005 ) . Mitochondria , oxidants , and aging . Cell 120 , 483 - 495 . 10 . 1016 / j . cell . 2005 . 02 . 001 . 6 . Murphy , M . P . ( 2009 ) . How mitochondria produce reactive oxygen species . Biochem J 417 , 1 - 13 . 10 . 1042 / BJ20081386 . 7 . Finkel , T . ( 2012 ) . Signal transduction by mitochondrial oxidants . J Biol Chem 287 , 4434 - 4440 . 10 . 1074 / jbc . R111 . 271999 . 8 . D ' Autreaux , B . , and Toledano , M . B . ( 2007 ) . ROS as signalling molecules : mechanisms that generate specificity in ROS homeostasis . Nat Rev Mol Cell Biol 8 , 813 - 824 . 10 . 1038 / nrm2256 . 9 . Meister , A . , and Anderson , M . E . ( 1983 ) . Glutathione . Annu Rev Biochem 52 , 711 - 760 . 10 . 1146 / annurev . bi . 52 . 070183 . 003431 . 10 . Mari , M . , Morales , A . , Colell , A . , Garcia - Ruiz , C . , Kaplowitz , N . , and Fernandez - Checa , J . C . ( 2013 ) . Mitochondrial glutathione : features , regulation and role in disease . Biochim Biophys Acta 1830 , 3317 - 3328 . 10 . 1016 / j . bbagen . 2012 . 10 . 018 . 11 . Rouault , T . A . , and Tong , W . H . ( 2008 ) . Iron - sulfur cluster biogenesis and human disease . Trends Genet 24 , 398 - 407 . 10 . 1016 / j . tig . 2008 . 05 . 008 . 12 . Lill , R . ( 2009 ) . Function and biogenesis of iron - sulphur proteins . Nature 460 , 831 - 838 . 10 . 1038 / nature08301 . 13 . Wang , Y . , Yen , F . S . , Zhu , X . G . , Timson , R . C . , Weber , R . , Xing , C . , Liu , Y . , Allwein , B . , Luo , H . , Yeh , H . W . , et al . ( 2021 ) . SLC25A39 is necessary for mitochondrial glutathione import in mammalian cells . Nature 599 , 136 - 140 . 10 . 1038 / s41586 - 021 - 04025 - w . 14 . Shi , X . , Reinstadler , B . , Shah , H . , To , T . L . , Byrne , K . , Summer , L . , Calvo , S . E . , Goldberger , O . , Doench , J . G . , Mootha , V . K . , and Shen , H . ( 2022 ) . Combinatorial GxGxE CRISPR screen identifies SLC25A39 in mitochondrial glutathione transport linking iron homeostasis to OXPHOS . Nat Commun 13 , 2483 . 10 . 1038 / s41467 - 022 - 30126 - 9 . 15 . Shi , X . , Reinstadler , B . , Shah , H . , To , T . - L . , Byrne , K . , Summer , L . , Calvo , S . E . , Goldberger , O . , Doench , J . G . , Mootha , V . K . , and Shen , H . ( 2021 ) . Combinatorial G x G x E CRISPR screening and functional analysis highlights SLC25A39 in mitochondrial GSH transport . bioRxiv , 2021 . 2009 . 2022 . 461361 . 10 . 1101 / 2021 . 09 . 22 . 461361 . 16 . Byrne , K . L . , Szeligowski , R . V . , and Shen , H . ( 2023 ) . Phylogenetic Analysis Guides Transporter Protein Deorphanization : A Case Study of the SLC25 Family of Mitochondrial Metabolite Transporters . Biomolecules 13 . 10 . 3390 / biom13091314 . 17 . Jumper , J . , Evans , R . , Pritzel , A . , Green , T . , Figurnov , M . , Ronneberger , O . , Tunyasuvunakool , K . , Bates , R . , Zidek , A . , Potapenko , A . , et al . ( 2021 ) . Highly accurate protein structure prediction with AlphaFold . Nature 596 , 583 - 589 . 10 . 1038 / s41586 - 021 - 03819 - 2 . 18 . Murphy , M . P . ( 2012 ) . Mitochondrial thiols in antioxidant protection and redox signaling : distinct roles for glutathionylation and other thiol modifications . Antioxid Redox Signal 16 , 476 - 495 . 10 . 1089 / ars . 2011 . 4289 . 19 . Requejo , R . , Hurd , T . R . , Costa , N . J . , and Murphy , M . P . ( 2010 ) . Cysteine residues exposed on protein surfaces are the dominant intramitochondrial thiol and may protect against oxidative damage . FEBS J 277 , 1465 - 1480 . 10 . 1111 / j . 1742 - 4658 . 2010 . 07576 . x . 20 . Nilsson , B . L . , Soellner , M . B . , and Raines , R . T . ( 2005 ) . Chemical synthesis of proteins . Annu Rev Biophys Biomol Struct 34 , 91 - 118 . 10 . 1146 / annurev . biophys . 34 . 040204 . 144700 . 21 . Cho , N . H . , Cheveralls , K . C . , Brunner , A . D . , Kim , K . , Michaelis , A . C . , Raghavan , P . , Kobayashi , H . , Savy , L . , Li , J . Y . , Canaj , H . , et al . ( 2022 ) . OpenCell : Endogenous tagging for the cartography of human cellular organization . Science 375 , eabi6983 . 10 . 1126 / science . abi6983 . 22 . Mathieson , T . , Franken , H . , Kosinski , J . , Kurzawa , N . , Zinn , N . , Sweetman , G . , Poeckel , D . , Ratnu , V . S . , Schramm , M . , Becher , I . , et al . ( 2018 ) . Systematic analysis of protein turnover in primary cells . Nat Commun 9 , 689 . 10 . 1038 / s41467 - 018 - 03106 - 1 . 23 . Zecha , J . , Meng , C . , Zolg , D . P . , Samaras , P . , Wilhelm , M . , and Kuster , B . ( 2018 ) . Peptide Level Turnover Measurements Enable the Study of Proteoform Dynamics . Mol Cell Proteomics 17 , 974 - 992 . 10 . 1074 / mcp . RA118 . 000583 . 24 . Morgenstern , M . , Peikert , C . D . , Lubbert , P . , Suppanz , I . , Klemm , C . , Alka , O . , Steiert , C . , Naumenko , N . , Schendzielorz , A . , Melchionda , L . , et al . ( 2021 ) . Quantitative high - confidence human mitochondrial proteome and its dynamics in cellular context . Cell Metab 33 , 2464 - 2483 e2418 . 10 . 1016 / j . cmet . 2021 . 11 . 001 . 25 . Chen , W . W . , Freinkman , E . , and Sabatini , D . M . ( 2017 ) . Rapid immunopurification of mitochondria for metabolite profiling and absolute quantification of matrix metabolites . Nat Protoc 12 , 2215 - 2231 . 10 . 1038 / nprot . 2017 . 104 . 26 . Chen , W . W . , Freinkman , E . , Wang , T . , Birsoy , K . , and Sabatini , D . M . ( 2016 ) . Absolute Quantification of Matrix Metabolites Reveals the Dynamics of Mitochondrial Metabolism . Cell 166 , 1324 - 1337 e1311 . 10 . 1016 / j . cell . 2016 . 07 . 040 . 27 . Horwich , A . L . , Fenton , W . A . , Chapman , E . , and Farr , G . W . ( 2007 ) . Two families of chaperonin : physiology and mechanism . Annu Rev Cell Dev Biol 23 , 115 - 145 . 10 . 1146 / annurev . cellbio . 23 . 090506 . 123555 . 28 . Arlt , H . , Tauer , R . , Feldmann , H . , Neupert , W . , and Langer , T . ( 1996 ) . The YTA10 - 12 complex , an AAA protease with chaperone - like activity in the inner membrane of mitochondria . Cell 85 , 875 - 885 . 10 . 1016 / s0092 - 8674 ( 00 ) 81271 - 4 . 29 . Di Bella , D . , Lazzaro , F . , Brusco , A . , Plumari , M . , Battaglia , G . , Pastore , A . , Finardi , A . , Cagnoli , C . , Tempia , F . , Frontali , M . , et al . ( 2010 ) . Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28 . Nat Genet 42 , 313 - 321 . 10 . 1038 / ng . 544 . 30 . Pierson , T . M . , Adams , D . , Bonn , F . , Martinelli , P . , Cherukuri , P . F . , Teer , J . K . , Hansen , N . F . , Cruz , P . , Mullikin For The Nisc Comparative Sequencing Program , J . C . , Blakesley , R . W . , et al . ( 2011 ) . Whole - exome sequencing identifies homozygous AFG3L2 mutations in a spastic ataxia - neuropathy syndrome linked to mitochondrial m - AAA proteases . PLoS Genet 7 , e1002325 . 10 . 1371 / journal . pgen . 1002325 . 31 . Srinivasan , V . , Pierik , A . J . , and Lill , R . ( 2014 ) . Crystal structures of nucleotide - free and glutathione - bound mitochondrial ABC transporter Atm1 . Science 343 , 1137 - 1140 . 10 . 1126 / science . 1246729 . 32 . Koppen , M . , Metodiev , M . D . , Casari , G . , Rugarli , E . I . , and Langer , T . ( 2007 ) . Variable and tissue - specific subunit composition of mitochondrial m - AAA protease complexes linked to hereditary spastic paraplegia . Mol Cell Biol 27 , 758 - 767 . 10 . 1128 / MCB . 01470 - 06 . 33 . Atorino , L . , Silvestri , L . , Koppen , M . , Cassina , L . , Ballabio , A . , Marconi , R . , Langer , T . , and Casari , G . ( 2003 ) . Loss of m - AAA protease in mitochondria causes complex I deficiency and increased sensitivity to oxidative stress in hereditary spastic paraplegia . J Cell Biol 163 , 777 - 787 . 10 . 1083 / jcb . 200304112 . 34 . Patron , M . , Tarasenko , D . , Nolte , H . , Kroczek , L . , Ghosh , M . , Ohba , Y . , Lasarzewski , Y . , Ahmadi , Z . A . , Cabrera - Orefice , A . , Eyiama , A . , et al . ( 2022 ) . Regulation of mitochondrial proteostasis by the proton gradient . EMBO J 41 , e110476 . 10 . 15252 / embj . 2021110476 . 35 . Luk , E . , Carroll , M . , Baker , M . , and Culotta , V . C . ( 2003 ) . Manganese activation of superoxide dismutase 2 in Saccharomyces cerevisiae requires MTM1 , a member of the mitochondrial carrier family . Proc Natl Acad Sci U S A 100 , 10353 - 10357 . 10 . 1073 / pnas . 1632471100 . 36 . Nilsson , R . , Schultz , I . J . , Pierce , E . L . , Soltis , K . A . , Naranuntarat , A . , Ward , D . M . , Baughman , J . M . , Paradkar , P . N . , Kingsley , P . D . , Culotta , V . C . , et al . ( 2009 ) . Discovery of genes essential for heme biosynthesis through large - scale gene expression analysis . Cell Metab 10 , 119 - 130 . 10 . 1016 / j . cmet . 2009 . 06 . 012 . 37 . Zhang , Y . , Pak , C . , Han , Y . , Ahlenius , H . , Zhang , Z . , Chanda , S . , Marro , S . , Patzke , C . , Acuna , C . , Covy , J . , et al . ( 2013 ) . Rapid single - step induction of functional neurons from human pluripotent stem cells . Neuron 78 , 785 - 798 . 10 . 1016 / j . neuron . 2013 . 05 . 029 . 38 . Fernandopulle , M . S . , Prestil , R . , Grunseich , C . , Wang , C . , Gan , L . , and Ward , M . E . ( 2018 ) . Transcription Factor - Mediated Differentiation of Human iPSCs into Neurons . Curr Protoc Cell Biol 79 , e51 . 10 . 1002 / cpcb . 51 . 39 . Pantazis , C . B . , Yang , A . , Lara , E . , McDonough , J . A . , Blauwendraat , C . , Peng , L . , Oguro , H . , Kanaujiya , J . , Zou , J . , Sebesta , D . , et al . ( 2022 ) . A reference human induced pluripotent stem cell line for large - scale collaborative studies . Cell Stem Cell 29 , 1685 - 1702 e1622 . 10 . 1016 / j . stem . 2022 . 11 . 004 . 40 . Sprenger , H . G . , MacVicar , T . , Bahat , A . , Fiedler , K . U . , Hermans , S . , Ehrentraut , D . , Ried , K . , Milenkovic , D . , Bonekamp , N . , Larsson , N . G . , et al . ( 2021 ) . Cellular pyrimidine imbalance triggers mitochondrial DNA - dependent innate immunity . Nat Metab 3 , 636 - 650 . 10 . 1038 / s42255 - 021 - 00385 - 9 . 41 . Quiros , P . M . , Langer , T . , and Lopez - Otin , C . ( 2015 ) . New roles for mitochondrial proteases in health , ageing and disease . Nat Rev Mol Cell Biol 16 , 345 - 359 . 10 . 1038 / nrm3984 . 42 . Liu , Y . , Liu , S . , Tomar , A . , Yen , F . S . , Unlu , G . , Ropek , N . , Weber , R . A . , Wang , Y . , Khan , A . , Gad , M . , et al . ( 2023 ) . Autoregulatory control of mitochondrial glutathione homeostasis . Science , eadf4154 . 10 . 1126 / science . adf4154 . 43 . Magri , S . , Fracasso , V . , Plumari , M . , Alfei , E . , Ghezzi , D . , Gellera , C . , Rusmini , P . , Poletti , A . , Di Bella , D . , Elia , A . E . , et al . ( 2018 ) . Concurrent AFG3L2 and SPG7 mutations associated with syndromic parkinsonism and optic atrophy with aberrant OPA1 processing and mitochondrial network fragmentation . Hum Mutat 39 , 2060 - 2071 . 10 . 1002 / humu . 23658 . Figure 1 . SLC25A39 ( A39 ) is a short - lived protein , and the degradation is regulated by GSH and the matrix cysteine residues . ( A ) AlphaFold prediction of A39 structure revealed a unique cysteine - rich matrix loop 1 . ( B ) Western blot of endogenous A39 and ectopically expressed FLAG - tagged A39 WT , substrate binding pocket mutant A39 C334S , and matrix loop 1 four cysteine mutant A39 4CA in the K562 cells upon GSH depletion by BSO treatment ( 1mM , 2d ) . GAPDH , loading control . ( C ) Mitochondrial GSH level assayed by HA - MITO tag immunoisolation followed by MS - based metabolite profiling in the control and clonal A39 CRIPSR KO K562 cells expressing the indicated A39 constructs . Statistical significance was calculated using two - tailed t test . Significance level was indicated as * * * p < 0 . 001 , * * p < 0 . 01 . Data are expressed as mean ± SD . ( D ) Scatter plot showing the correlation of protein abundance ( log 10 nM ) and mRNA abundance ( Log 10 TPM ) for all coding genes expressed in the HEK293 cells ( OpenCell , CZI ) . Blue dots , SLC25 transporter proteins . A39 and A40 are highlighted in red . ( E - F ) Western blot showing A39 - FLAG ( E ) and A39 4CA - FLAG ( F ) protein level in the clonal A39 CRISPR KO K562 cells treated with CHX ( cycloheximide , 150 µ g / ml ) for the indicated times , either under basal condition ( - BSO ) or with BSO ( 1mM and with 2 d prior treatment ) . GAPDH , loading control . A39 band intensity was quantified and modeled using the non - linear fitting with one phase decay ( A39 , - BSO ; A39 4CA , - BSO and + BSO ) and plateau followed by one phase decay ( A39 , + BSO ) . Figure 2 . Co - immunoprecipitation mass spectrometry and CRISPR KO identify the mitochondrial m - AAA protease AFG3L2 in A39 degradation . ( A ) Left , flow chart showing the experimental procedure to identify putative A39 - interacting regulatory proteins . Right , silver stained SDS - PAGE of anti - FLAG immunoprecipitants from the control and A39 - FLAG mitochondrial lysates . Wild type K562 cells expressing 3HA - eGFP - OMP25 were used as control . A39 - FLAG protein identified by MS is labeled ; * , a specific binding partner HSPD1 identified by MS . ( B ) Categorization of specific A39 - interacting protein hits into relevant quality control pathways . Protein level intensity based on top three peptides was shown in the control and A39 - FLAG co - immunoprecipitants . Bold , hits that were followed up by CRISPR KO . ( C ) Western blot of A39 from CRISPR KO K562 cells using sgRNAs targeting indicated A39 - interacting proteins , and related mitochondrial proteases . Cells were analyzed under basal condition and BSO ( 200 µ M ) treatment for either 1 d or 2 d . Two CRISPR KO lines that increased basal A39 level were highlighted in red . GAPDH , loading control . ( D - E ) Western blot of endogenous A39 , ectopically expressed FLAG - tagged A39 WT and A39 4CA in the AFG3L2 CRISPR KO cells ( + sgAFG3L2 , D ) and ABCB7 CRISPR KO cells ( + sgABCB7 , E ) . ( F ) Western blot of endogenous A39 in HeLa cells upon AFG3L2 CRISPR KO and re - expressing AFG3L2 - 3xFLAG . GAPDH , loading control . ( G ) Western blot of the endogenous A39 protein in the K562 cells treated with CHX ( cycloheximide , 150 µ g / ml ) for the indicated times , with or without AFG3L2 CRISPR KO . GAPDH , loading control . ( H ) A39 band intensity was quantified and modeled by the non - linear fitting with one phase decay . Figure 3 . A39 degradation is targeted through the matrix loop 1 , which controls mitochondrial glutathione uptake and steady state level . ( A ) Sequence alignment showing matrix loop 1 of A39 , SLC25A40 , and other representative SLC25 transporters SLC25A15 , SLC25A1 and SLC25A11 . ( B ) Diagram showing Loop 1 swapping chimeric constructs . ( C ) FLAG western blot for the indicated constructs in the clonal A39 CRISPR KO K562 cells , upon AFG3L2 CRISPR KO ( + sgAFG3L2 ) . GAPDH , loading control . ( D ) Western blot of endogenous A39 in the whole cell lysates and mitochondrial lysates from the control and AFG3L2 CRISPR KO K562 cells . Mitochondrial protein VDAC , loading control . ( E ) Mitochondrial GSH level assayed by HA - MITO tag immunoisolation followed by MS - based metabolite profiling in the control and AFG3L2 CRIPSR KO K562 cells , normalized by total protein abundance . ( F ) Western blot of A39 from BSO ( 1mM , 2 d ) - treated clonal A39 CRISPR KO cells expressing either wild type A39 and A39 4CA - FLAG . VDAC , loading control . ( G ) GSH uptake ( 1mM labeled GSH + 4mM unlabeled GSH , 15 min at room temperature ) into HA - MITO immunoisolated mitochondria from BSO - treated clonal A39 CRISPR KO cells expressing either wild type A39 or A39 4CA - FLAG . ( H ) Western blot of A39 WT and A39 A11L1 - FLAG in the clonal A39 CRISPR KO cells . ( I ) Mitochondrial GSH level assayed by HA - MITO tag immunoisolation followed by MS - based metabolite profiling in control , A39 CRISPR KO , and A39 CRISPR KO re - expressing A39 WT , or A39 A11L1 - FLAG , normalized by NAD + level . ( J ) GSH uptake ( 5mM labeled GSH , 15 min at room temperature ) into isolated mitochondria from A39 CRISPR KO cells expressing A39 WT and A39 A11L1 - FLAG . All statistical significance was calculated using two - tailed t test . Significance level was indicated as * * * p < 0 . 001 , * * p < 0 . 01 . Data are expressed as mean ± SD . Figure 4 . A39 is stabilized through a coordinated sensing of mitochondrial iron - sulfur cluster by the matrix cysteines . A39 regulation occurs in neurons . ( A ) Western blot of A39 showing BSO treatment ( 1mM , 2d ) increased A39 in the control K562 cells but did not affect NDUFA9 level , while the basal level of A39 and NDUFA9 were increased in the AFG3L2 CRISPR KO K562 cells . ( B ) Diagram of iron manipulation strategies . ( C ) Western blot of A39 in K562 cells treated with either or a combination of BSO ( 1mM , 2d ) and DFO ( 20 µ M , 2d ) . ( D ) Western blot of A39 with and without BSO ( 1mM , 2d ) in the CRISPR KO K562 cells of either or both mitochondrial iron transporters SLC25A28 and SLC25A37 . ( E ) Western blot of A39 upon BSO ( 1mM ) treatment for 1 and 2d in the CRISPR KO K562 cells of HSCB or GLRX5 . ( F ) Diagram of A39 cysteine labeling and mobility shift assay . Cells were treated with either or a combination of BSO ( 100 µ M , 2d ) and DFO ( deferoxamine , 20 µ M , 2d ) . ( G ) Anti - FLAG western blot and mobility shift assay for A39 - FLAG in the indicated conditions , without or with cysteine labeling . ( H ) Diagram of neuronal differentiation from the iPSC line , KOLF2 . 1J cells expressing dox - inducible NGN2 in the safe locus . ( I ) Western blot of A39 , HSCB , AFG3L2 , and Synaptophysin , a synaptic marker from the indicated days ( H ) during neuronal differentiation . GAPDH , loading control . ( J ) Western blot of A39 in the mature iNeurons ( differentiation Day 21 ) upon 1 mM BSO treatment for 3 and 7 d . GAPDH , loading control . ( K ) Western blot of A39 and IRP2 in the mature iNeurons ( differentiation Day 21 ) , treated with either or a combination of BSO ( 1mM , 7d ) and DFO ( 20 µ M , 7d ) . GAPDH , loading control . ( L ) A39 regulation model . Figure S1 Western blot of A39 ( A ) and the paralogous SLC25A40 ( C ) in the K562 cells treated with 1mM BSO for 2d . * , SLC25A40 band . A39 mRNA level does not change upon BSO treatment ( B ) . Figure S2 ( A ) Western blot of A39 and FLAG for the endogenous A39 , ectopically expressed A39FLAG ( without flexible linker ) , A39 - FLAG ( with flexible linker ) in the A39 CRISPR KO K562 cells , with or without 1mM BSO treatment for 2d . ( B ) Validation of AFG3L2 and ABCB7 CRISPR KO K562 cells by reduced mRNA level through nonsense mediated decay . ( C ) A39 mRNA level is unchanged in the AFG3L2 and ABCB7 CRISPR KO cells . Figure S3 Validation of iron manipulation . ( A ) Western blot of IRP2 upon BSO ( 1mM , 2d ) and DFO ( 20 µ M , 2d ) treatment . ( B ) Western blot of A39 and IRP2 from the A39 CRISPR KO K562 cells expressing A39 - FLAG upon BSO ( 1mM , 2d ) and DFO ( 20 µ M , 2d ) treatment . ( C ) Western blot of SLC25A37 from the control and SLC25A39 CRISPR KO K562 cells upon BSO treatment ( 1mM , 2d ) . ( D ) Validation of SLC25A28 CRISPR KO by reduced SLC25A28 mRNA level through nonsense mediated decay . Statistical significance was calculated using two - tailed t test . Significance level was indicated as * * * p < 0 . 001 . Data are expressed as mean ± SD . ( E - F ) Western blot of HSCB ( E ) and GLRX5 ( F ) in the corresponding CRISPR KO K562 cells . ( G ) A39 western blot for the endogenous A39 , ectopically expressed A39 WT and single cysteine mutants A39 C74A , A39 C78A , A39 C88A , A39 C94A in the A39 CRISPR KO K562 cells upon BSO treatment ( 1mM , 2d ) . ( H ) Cell morphology of iPSCs , developing neurons ( Day 9 post differentiation ) , and mature neurons ( Day 21 post differentiation ) . Scale bar , 100 µ m . + + + + - - - - A B D E F SLC25A39 KO A39 WT A39 C334S A39 4CA - FLAG BSO SLC25A39 GAPDH 0 0 . 5 1 1 . 5 2 I n t en s i t y ( A . U . ) m i t o c hond r i a l G S H ×10 10 - ctrl SLC25A39 KO A 3 9 W T A 3 9 C 334 S A 3 9 4 C A AlphaFold prediction of SLC25A39 - 2 - 1 0 1 2 3 4 - 2 - 1 0 1 2 3 4 SLC25A39 SLC25A40 SLC25 transporters all proteins protein - mRNA correlation in HEK293T cells mRNA abundance ( log 10 TPM ) P r o t e i n abundan c e ( l og 10 n M ) 0 1 2 3 4 5 6 7 8 0 50 100 Time ( hr ) S L C 25 A 39 l e v e l ( % ) + BSO - BSO C * * * * * * * * * * * IMS C78 matrix 23 . 29 per - residue confidence score ( pLDDT ) 95 . 67 C74 C88 C94 T M 1 T M 2 T M 3 T M 4 T M 5 T M 6 loop 1 CHX ( hr ) 0 1 2 6 4 8 SLC25A39 GAPDH SLC25A39 GAPDH - BS O + B S O A39 KO + A39 WT - FLAG 0 1 2 3 4 5 6 7 8 0 50 100 Time ( hr ) S L C 25 A 39 l e v e l ( % ) + BSO - BSO CHX ( hr ) SLC25A39 GAPDH SLC25A39 GAPDH 0 2 6 4 8 A39 KO + A39 4CA - FLAG - BS O + B S O C334 Figure 1 IP : HA , FLAG ctrl + BSO 37 50 25 75 150 kDa * A39 - FLAG BSO ( d ) HSPA9 HSPD1 1 2 1 1 1 2 2 2 PHB1 AFG3L2 STOML2 1 1 1 2 2 2 GHITM 2 SLC25A39 GAPDH CRISPR KO - - C D A B mitochondria isolation HA - MITO IP ( 3xHA - eGFP - OMP25 ) FLAG immunoprecipitation ( SLC25A39 - FLAG ) SDS - PAGE and mass spec proteomics A39 KO + A39 - FLAG K562 clonal cell selection ( A39 CRISPR KO + A39 - FLAG ) BSO treatment 2d CLPB SPG7 1 2 1 1 1 2 2 2 YME1L LONP1 ABCB7 1 2 1 1 2 2 2 PMPCA PMPCB 2 - - - - - - - - - - - - - - - - - - - SLC25A39 GAPDH sgAFG3L2 A39 WT A39 4CA A39 KO - + - + - + A39 WT A39 4CA A39 KO E SLC25A39 GAPDH sgABCB7 - + - + - + SLC25A39 GAPDH AFG3L2 AFG3L2 - 3xFLAG sgAFG3L2 HeLa F - + - + 0 1 2 6 4 8 0 1 2 3 4 5 6 7 8 0 50 100 Time ( hr ) S L C 25 A 39 l e v e l ( % ) AFG3L2 KO ctrl G H c t r l A F G 3L2 K O CHX ( hr ) SLC25A39 GAPDH SLC25A39 GAPDH A39 - interacting proteins from MS by relavent pathways ctrl A39 - FLAG HSPD1 0 1 . 6E + 09 TRAP1 0 1 . 7E + 07 HSPA8 0 3 . 6E + 06 STOML2 0 1 . 2E + 07 PHB1 0 1 . 0E + 07 GHITM 0 1 . 0E + 07 AFG3L2 0 5 . 7E + 06 PMPCB 0 2 . 6E + 06 PMPCA 0 1 . 8E + 06 CLPB 0 1 . 5E + 06 LONP1 0 1 . 3E + 06 ABCB7 0 1 . 9E + 06 HSPA9 8 . 4E + 07 2 . 5E + 08 matrix chaperone mitophagyrelated proteaserelated iron related Figure 2 FLAG GAPDH SLC25A39 VDAC A C D E ×10 9 0 0 . 5 1 1 . 5 2 2 . 5 I n t en s i t y ( A . U . ) mito GSH ×10 8 A39 KO ×10 9 0 0 . 5 1 1 . 5 - c t r l SLC25A39 KO A 39 W T A 39 A 11L1 ×10 8 2 10 8 6 4 0 * * * * * * * * * B sgAFG3L2 - + - + - + - + - + A39 A40 A39 4CA A39 A11L1 A39 A40L1 SLC25A39 KO sgAFG3L2 - + - + cell mito * * sgAFG3L2 - + SLC25A39 GAPDH SLC25A39 KO - - A39 A39 A11L1 mito GSH I n t en s i t y ( A . U . ) A 39 W T A 39 A 11L1 I n t en s i t y ( A . U . ) SLC25A39 KO * * * SLC25A39 VDAC A39 A39 4CA BSO + + I n t en s i t y ( A . U . ) 0 A39 KO A39 A39 4CA BSO + + * * * mito GSH [ M + 3 ] uptake mito GSH [ M + 3 ] uptake F G H I J SLC25A39 A40L1 SLC25A39 A11L1 FLAG SLC25A39 WT FLAG FLAG A40 - Loop1 TM1 TM2 TM3 TM4 TM5 TM6 A11 - Loop1 Loop 1 swapping chimeric constructs : - FLAG - FLAG SLC25A39SLC25A40SLC25A15 SLC25A1 SLC25A11 TM1 Loop 1 TM2 TM3 TM4 TM5 TM6 SQRPSMASELMPSSRLWSLSYTKLPSSLQSTGKCLLYCN - - GV - LEPLYL - CPNGARCATWFQDPT - RFTG AQNNPL - - - - - - - - - - - - - - - - - - PK - - - - - GKCFVYSN - - GL - MDHLCV - CEEGGN - KLWYKKPG - NFQG - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - TFPDLYRG LDE - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - RSHPPRYRG LSGE - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - GAKTREYKT 1 2 3 4 5 Figure 3 + + - - - - + + A39 GAPDH A D DFOBSO - - - - 1 2 1 1 2 2 HSCB KO GLRX5 KO A39 GAPDH BSO ( d ) Fe 2 + A37 Fe 2 + Deferoxamine ( DFO ) Cysteine ISCU A28 HSCBGLRX5 protein [ 2Fe - 2S ] protein [ 4Fe - 4S ] Fe - S ? ISCU [ 2Fe - 2S ] GSH SLC25A28SLC25A37 ( A28 , A37 DKO ) HSCB KO GLRX5 KO ABCB7 C 1 2 BSO ( d ) AFG3L2 KO - 1 2 NDUFA9 AFG3L2 A39 GAPDH ctrl - + + + + - - - - A39 GAPDH BSO A28 KO A37 KO A28 , A37 DKO F E SLC25A39 GAPDH BSO ( d ) - 3 7 0 3 7 14 21 days SLC25A39 AFG3L2 Synaptophysin GAPDH HSCB H Day - 1 Day 2 BrainPhys + BDNF + NT - 3 + B27 + Laminin + Dox Day 3 Day 14 Day 1 DMEM / F12 + Dox E8 Flex + ROCKi Day 21 E8 Flex Day 0 iPSC - derived glutaminergic neuronal differentiation I iPSC neuronal differentiation iNeurons ( Day 21 ) J IMM IMS matrix AFG3L2 SLC25A39 low GSH high iron Fe - S SLC25A39 protein matrix GSH SLC25A39 protein matrix GSH SLC25A39 + - + + + - + - + + + - FLAG A39 , AFG3L2 KO + A39 WT - FLAG mitochondrial lysates DFOBSO * * * - labeling + labeling BSO or DFO - treated K562 cells ( A39 KO + A39 - FLAG , AFG3L2 KO ) I NH O O HN O S NH HN O O mitochondria isolation reactive cysteine labeling FLAG western blot for mobility shift Iodoacetyl - PEG2 - Biotin , MW = 542 Da GAPDH SLC25A39 IRP2 + - + + + - - - B G K L iNeurons ( Day 21 ) DFOBSO Figure 4 SLC25A39 mRNA R e l a t i v e m RN A l e v e l 0 . 0 0 . 2 0 . 4 0 . 6 0 . 8 1 . 0 1 . 2 BSO BSO SLC25A39 GAPDH SLC25A40 VDAC A n . s . + - BSO + - B + - * C Figure S1 SLC25A39 SLC25A39 KO BSO FLAG ctrl - - SLC25A39 KO A 3 9 F L A G A 3 9 - F L A G ctrl A 3 9 F L A G A 3 9 - F L A G A39FLAG : no linker , pooled cells A39 - FLAG : with linker , clonal selected cells AFG3L2 R e l a t i v e m RN A l e v e l c t r l A F G 3L2 K O 0 . 0 0 . 5 1 . 0 1 . 5 ABCB7 R e l a t i v e m RN A l e v e l c t r l A B C B 7 K O 0 . 0 0 . 5 1 . 0 1 . 5 R e l a t i v e m RN A l e v e l c t r l A B C B 7 K O 0 . 0 0 . 5 1 . 0 1 . 5 * * * * * * SLC25A39 mRNA level R e l a t i v e m RN A l e v e l c t r l A F G 3L2 K O 0 . 0 0 . 5 1 . 0 1 . 5 n . s . n . s . A B C Figure S2 + + - - - - - + + - IREB2 ( IRP2 ) GAPDH GAPDH SLC25A37 SLC25A28 mRNA R e l a t i v e m RN A l e v e l c t r l A 28 K O 0 . 0 0 . 5 1 . 0 1 . 5 GLRX5 + - A D B BSO DFO + + + + - - - - - - - + + + + - + + + + - - - - sgSLC25A28 sgSLC25A37 BSO - - - - HSCB GAPDH + - E sgHSCB sgGLRX5 * * * GAPDH IREB2 GAPDH SLC25A39 + + - - - - - + + - BSO DFO A39 KO + A39 - FLAG C iPSCs Day 9 G A39 WT A39 C78A - FLAG A39 C74A + + + + - - - - A39 WT A39 C94A - FLAG A39 C88A + + + + - - - - SLC25A39 GAPDH BSO SLC25A39 KO SLC25A39 KO F H iNeurons ( Day 21 ) Figure S3